IPO registrations (S-1, F-1) · Registrants
BriaCell Therapeutics Corp.
- SEC CIK
- 1610820 · filings on EDGAR ↗
- Former names
- Ansell Capital Corp. (2014–2014)
- Registration
- Form F-1, S-1, first filed 2019-10-22, last 2025-12-23; 5 initial registrations, 18 amendments
- Outcome
- Final prospectus filed 2021-02-25; declared effective 2021-02-23
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- A1
- Business address
- 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, West Vancouver, A1 V7T 2X1
- Ticker
- BCTX, BCTXL, BCTXZ (Nasdaq, Nasdaq, Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- BriaCell Therapeutics Corp. on the corporate pages
Offering terms
- Proposed price range
- $4.25–$5.00 per share (F-1/A filed 2021-02-18)
- Final price
- $4.25 per share, within the range (424B4 filed 2021-02-25, an initial public offering)
- Listing
- Nasdaq under the symbol BCTX
- Lead underwriters
- ThinkEquity
- Syndicate
- of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: BriaCell Therapeutics Corp. EXACT (CIK (EXACT))
- SEC filer: BriaCell Therapeutics Corp. EXACT (CIK (EXACT))
Filings 40
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-10-22 | F-1 | F-1 (foreign registration) | BriaCell Therapeutics Corp. | 0001493152-19-015838 ↗ |
| 2019-11-12 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-19-016844 ↗ |
| 2019-11-27 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-19-018524 ↗ |
| 2020-01-21 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-000871 ↗ |
| 2020-01-23 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-000985 ↗ |
| 2020-02-21 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-002799 ↗ |
| 2020-03-13 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-003911 ↗ |
| 2020-05-18 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-009237 ↗ |
| 2020-05-27 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-009927 ↗ |
| 2020-09-18 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-017990 ↗ |
| 2020-10-20 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-019645 ↗ |
| 2020-12-10 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-023253 ↗ |
| 2020-12-23 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-20-024156 ↗ |
| 2021-01-15 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-21-001108 ↗ |
| 2021-02-03 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-21-002440 ↗ |
| 2021-02-18 | F-1/A | F-1/A (amendment) | BriaCell Therapeutics Corp. | 0001493152-21-004274 ↗ |
| 2021-02-23 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-21-000708 ↗ |
| 2021-02-25 | 424B4 | 424B4 (final prospectus) | BriaCell Therapeutics Corp. | 0001493152-21-004840 ↗ |
| 2021-02-26 | 424B4 | 424B4 (final prospectus) | BriaCell Therapeutics Corp. | 0001493152-21-004866 ↗ |
| 2021-06-15 | F-1 | F-1 (foreign registration) | BriaCell Therapeutics Corp. | 0001493152-21-014365 ↗ |
| 2021-06-24 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-21-002511 ↗ |
| 2021-11-23 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-21-004457 ↗ |
| 2022-03-16 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-22-000649 ↗ |
| 2023-03-28 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-23-000686 ↗ |
| 2024-01-31 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-24-000271 ↗ |
| 2025-04-22 | S-1 | S-1 (registration) | BriaCell Therapeutics Corp. | 0001641172-25-005677 ↗ |
| 2025-04-23 | S-1/A | S-1/A (amendment) | BriaCell Therapeutics Corp. | 0001641172-25-005871 ↗ |
| 2025-04-24 | S-1MEF | S-1MEF (added securities) | BriaCell Therapeutics Corp. | 0001641172-25-006036 ↗ |
| 2025-04-24 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-25-001243 ↗ |
| 2025-04-28 | 424B4 | 424B4 (final prospectus) | BriaCell Therapeutics Corp. | 0001641172-25-006359 ↗ |
| 2025-04-28 | 424B4 | 424B4 (final prospectus) | BriaCell Therapeutics Corp. | 0001641172-25-006361 ↗ |
| 2025-07-08 | S-1 | S-1 (registration) | BriaCell Therapeutics Corp. | 0001641172-25-018193 ↗ |
| 2025-07-09 | S-1/A | S-1/A (amendment) | BriaCell Therapeutics Corp. | 0001641172-25-018347 ↗ |
| 2025-07-10 | S-1/A | S-1/A (amendment) | BriaCell Therapeutics Corp. | 0001641172-25-018633 ↗ |
| 2025-07-15 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-25-002260 ↗ |
| 2025-07-16 | 424B4 | 424B4 (final prospectus) | BriaCell Therapeutics Corp. | 0001641172-25-019807 ↗ |
| 2025-12-23 | S-1 | S-1 (registration) | BriaCell Therapeutics Corp. | 0001493152-25-028916 ↗ |
| 2026-01-13 | S-1MEF | S-1MEF (added securities) | BriaCell Therapeutics Corp. | 0001493152-26-002103 ↗ |
| 2026-01-13 | EFFECT | EFFECT (declared effective) | BriaCell Therapeutics Corp. | 9999999995-26-000157 ↗ |
| 2026-01-14 | 424B4 | 424B4 (final prospectus) | BriaCell Therapeutics Corp. | 0001493152-26-002258 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-02-18 | F-1/A | registration statement | $4.25–$5.00 | - | - | Nasdaq BCTX | 2 | primary document; range, cover names 2 | document ↗ | |
| 2021-02-25 | 424B4 | final prospectus | $4.25 | - | - | Nasdaq BCTX | 2 | primary document; price table, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Del Priore Giuseppe | Officer | Chief Medical Officer | 1 | 2022 | |
| Embro-Pantalony Vaughn C. | Director | 1 | 2022 | ||
| Gross Jane A | Director | 1 | 2022 | ||
| LEVIN GADI | Officer | CFO & Secretary | 1 | 2022 | |
| Lopez-Lago Miguel A. | Officer | Chief Scientific Officer | 1 | 2022 | |
| Schmieg Martin E. | Director | 1 | 2022 | ||
| Taub Rebecca | Director | 1 | 2022 | ||
| Williams Williams V. | Director,Officer | President & CEO; President, CEO | 2 | 2022 | |
| Lustig Marc | Director; Director,TenPercentOwner | 2 | 2022–2024 | ||
| Bondarenko Jamieson | Director; Director,Officer | Chairman | 3 | 2022 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-06-15 | BriaCell Therapeutics Corp. | Pharmaceuticals | $27,195,924 | $27,195,924 | 12 | 1 |
| 2018-04-10 | BriaCell Therapeutics Corp. | Biotechnology | $800,000 | $800,000 | 3 | 1 |
| 2014-12-12 | BriaCell Therapeutics Corp. | Biotechnology | $6,006,150 | $6,006,150 | 7 | 1 |
| 2014-06-20 | Ansell Capital Corp. | Other | $881,274 | $299,301 | 7 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | BriaCell Therapeutics Corp. | Form D private offerings | CIK (EXACT) | |
| SEC filer | BriaCell Therapeutics Corp. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, A1 first:
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
- Old API Wind-down Ltd. A1
- AbCellera Biologics Inc. A1
- BODY & MIND INC. A1
- XORTX Therapeutics Inc. A1
In other datasets, the same topic (Health) in A1:
- Form D issuer: 1219014 B.C. Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health